1. Home
  2. RGEN vs GGAL Comparison

RGEN vs GGAL Comparison

Compare RGEN & GGAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGEN
  • GGAL
  • Stock Information
  • Founded
  • RGEN 1981
  • GGAL 1905
  • Country
  • RGEN United States
  • GGAL Argentina
  • Employees
  • RGEN N/A
  • GGAL N/A
  • Industry
  • RGEN Medical/Dental Instruments
  • GGAL Commercial Banks
  • Sector
  • RGEN Health Care
  • GGAL Finance
  • Exchange
  • RGEN Nasdaq
  • GGAL Nasdaq
  • Market Cap
  • RGEN 8.0B
  • GGAL 9.4B
  • IPO Year
  • RGEN N/A
  • GGAL N/A
  • Fundamental
  • Price
  • RGEN $126.50
  • GGAL $62.02
  • Analyst Decision
  • RGEN Buy
  • GGAL Strong Buy
  • Analyst Count
  • RGEN 12
  • GGAL 4
  • Target Price
  • RGEN $172.67
  • GGAL $59.00
  • AVG Volume (30 Days)
  • RGEN 815.5K
  • GGAL 1.1M
  • Earning Date
  • RGEN 04-29-2025
  • GGAL 01-01-0001
  • Dividend Yield
  • RGEN N/A
  • GGAL 3.83%
  • EPS Growth
  • RGEN N/A
  • GGAL 120.03
  • EPS
  • RGEN N/A
  • GGAL 1.06
  • Revenue
  • RGEN $650,429,000.00
  • GGAL $6,697,505,438.00
  • Revenue This Year
  • RGEN $13.93
  • GGAL $11.73
  • Revenue Next Year
  • RGEN $14.35
  • GGAL N/A
  • P/E Ratio
  • RGEN N/A
  • GGAL $6.44
  • Revenue Growth
  • RGEN 4.88
  • GGAL N/A
  • 52 Week Low
  • RGEN $102.97
  • GGAL $23.53
  • 52 Week High
  • RGEN $182.52
  • GGAL $74.00
  • Technical
  • Relative Strength Index (RSI)
  • RGEN 44.61
  • GGAL 57.33
  • Support Level
  • RGEN $123.10
  • GGAL $60.24
  • Resistance Level
  • RGEN $135.47
  • GGAL $63.69
  • Average True Range (ATR)
  • RGEN 6.98
  • GGAL 2.35
  • MACD
  • RGEN -0.97
  • GGAL 0.16
  • Stochastic Oscillator
  • RGEN 25.20
  • GGAL 77.22

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

About GGAL Grupo Financiero Galicia S.A.

Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. It generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.

Share on Social Networks: